Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 6/20 | 0.43 |
| ▸ | CDK2 | P24941 | 6/20 | 0.43 |
| ▸ | CCNK | O75909 | 2/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.43 |
| ▸ | CCR6 | P51684 | 9/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670694 | 0.90 | CCNA2 (0.53) | CCNA2CDK2CCNKCDK12CCR6 | |
| SCHEMBL32670455 | 0.90 | CCNA2 (0.41) | CCNA2CDK2CCNKCDK12CCR6 | |
| SCHEMBL32670630 | 0.88 | CDK2 (0.46) | CCNA2CDK2CCNKCDK12CCR6 | |
| SCHEMBL32670631 | 0.85 | CCR6 (0.42) | CCNA2CDK2CCNKCDK12CCR6 | |
| SCHEMBL32670453 | 0.84 | CCR6 (0.46) | CCNA2CDK2CCNKCDK12CCR6 | |
| SCHEMBL32670652 | 0.82 | NAMPT (0.48) | CCNA2CDK2CCNKCDK12CCR6 | |
| SCHEMBL32670463 | 0.80 | CCNA2 (0.51) | CCNA2CDK2CCNKCDK12CCR6 | |
| SCHEMBL32670629 | 0.78 | CCR6 (0.47) | CCNA2CDK2CCNKCDK12CCR6 | |
| SCHEMBL32670559 | 0.78 | CCR6 (0.49) | CCNA2CDK2CCNKCDK12CCR6 | |
| SCHEMBL32670540 | 0.78 | CCR6 (0.46) | CCNA2CDK2CCNKCDK12CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | claimed |
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | CCNA2 3190/4885CDK2 1610/4885CCNK 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.